Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

NOD1/NOD2-mediated recognition of non-typeable Haemophilus influenzae activates innate immunity during otitis media.

Lee J, Leichtle A, Zuckerman E, Pak K, Spriggs M, Wasserman SI, Kurabi A.

Innate Immun. 2019 Nov;25(8):503-512. doi: 10.1177/1753425919872266. Epub 2019 Aug 31. No abstract available.

PMID:
31474163
2.

Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras.

Peiffer KH, Kuhnhenn L, Stelzl E, Dietz J, Susser S, Tal AO, Finkelmeier F, Zuckerman E, Cornberg M, Barak M, Piazzolla V, Mangia A, Zeuzem S, Kessler HH, Vermehren J, Sarrazin C.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e00060-19. doi: 10.1128/JCM.00060-19. Print 2019 Jul.

PMID:
31043467
3.

[ELABORATION AND TREATMENT DECISION IN INCIDENTAL SPLANCHNIC VEIN THROMBOSIS].

Rozano Gorelick A, Zuckerman E.

Harefuah. 2019 Mar;158(3):176-179. Hebrew.

PMID:
30916505
4.

High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.

Gozlan Y, Bucris E, Shirazi R, Rakovsky A, Ben-Ari Z, Davidov Y, Veizman E, Saadi T, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Katchman H, Menachem Y, Safadi R, Galun E, Zuckerman E, Nimer A, Hazzan R, Maor Y, Saif AM, Etzion O, Lurie Y, Mendelson E, Mor O.

Antivir Ther. 2019;24(3):221-228. doi: 10.3851/IMP3301.

PMID:
30880684
5.

Increased killer B cells in chronic HCV infection may lead to autoimmunity and increased viral load.

Eiza N, Zuckerman E, Carlebach M, Rainis T, Goldberg Y, Vadasz Z.

Clin Exp Immunol. 2018 Aug;193(2):183-193. doi: 10.1111/cei.13139.

6.

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.

Brown A, Hézode C, Zuckerman E, Foster GR, Zekry A, Roberts SK, Lahser F, Durkan C, Badshah C, Zhang B, Robertson M, Wahl J, Barr E, Haber B; C-SCAPE Study Investigators.

J Viral Hepat. 2018 May;25(5):457-464. doi: 10.1111/jvh.12801. Epub 2018 Mar 14.

PMID:
29152828
7.

Digital Health Communication and Global Public Influence: A Study of the Ebola Epidemic.

Roberts H, Seymour B, Fish SA 2nd, Robinson E, Zuckerman E.

J Health Commun. 2017;22(sup1):51-58. doi: 10.1080/10810730.2016.1209598.

PMID:
28854128
8.

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10.

PMID:
28802816
9.

Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.

Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C.

J Hepatol. 2017 Oct;67(4):680-686. doi: 10.1016/j.jhep.2017.05.027. Epub 2017 Jun 13.

PMID:
28619439
10.

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.

Wedemeyer H, Craxí A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, Calleja JL.

J Viral Hepat. 2017 Nov;24(11):936-943. doi: 10.1111/jvh.12722. Epub 2017 Jul 3.

PMID:
28480525
11.

HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.

Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski T, Weiss P, Cohen-Ezra O, Lurie Y, Gafanovich I, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Zuckerman E, Carmiel-Haggai M, Nimer A, Hazzan R, Maor Y, Kitay-Cohen Y, Shemer-Avni Y, Kra-Oz Z, Schreiber L, Peleg O, Sierra S, Harrigan PR, Mendelson E, Mor O.

Antivir Ther. 2017;22(5):431-441. doi: 10.3851/IMP3123. Epub 2017 Jan 9.

PMID:
28067632
12.

Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.

Gane E, Ben Ari Z, Mollison L, Zuckerman E, Bruck R, Baruch Y, Howe AY, Wahl J, Bhanja S, Hwang P, Zhao Y, Robertson MN.

J Viral Hepat. 2016 Oct;23(10):789-97. doi: 10.1111/jvh.12552. Epub 2016 Jun 12.

PMID:
27291249
13.

Delayed Bleeding after Percutaneous Liver Biopsy.

Dotan Y, Carlebach M, Zuckerman E, Maruf M, Schiff E.

Eur J Case Rep Intern Med. 2016 Jan 18;3(2):000359. doi: 10.12890/2016_000359. eCollection 2016.

14.

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londoño MC, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen BY, Robertson M, Barr E, Wahl J, Greaves W.

Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5. Erratum in: Lancet. 2015 Nov 7;386(10006):1824.

PMID:
26456905
15.

Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.

Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Forns X.

Clin Infect Dis. 2016 Jan 1;62(1):32-6. doi: 10.1093/cid/civ722. Epub 2015 Sep 14.

PMID:
26371152
16.

Secondary sclerosing cholangitis following major burn.

Ben-Ari Z, Levingston D, Weitzman E, Haviv-Yadid Y, Cohen-Ezra O, Weiss P, Zuckerman E, Inbar Y, Amitai M, Rimon U, Goder M, Haik J.

Ann Hepatol. 2015 Sep-Oct;14(5):695-701.

17.

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.

Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Palcza J, Howe AY, DiNubile MJ, Robertson MN, Wahl J, Barr E, Buti M.

J Hepatol. 2015 Sep;63(3):564-72. doi: 10.1016/j.jhep.2015.04.009. Epub 2015 Apr 18.

PMID:
25895428
18.

When politics froze fashion: the effect of the Cultural Revolution on naming in Beijing.

Obukhova E, Zuckerman EW, Zhang J.

AJS. 2014 Sep;120(2):555-83.

PMID:
25811071
20.

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.

Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, Shestakova I, Nymadawa P, Blach S, Acharya S, Anand AC, Andersson MI, Arendt V, Arkkila P, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Gadano AC, Gower E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kostrzewska K, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Norris S, Nurmukhametova E, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Schréter I, Shah SR, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Prabdial-Sing N, Flisiak R, Estes C.

J Viral Hepat. 2015 Jan;22 Suppl 1:46-73. doi: 10.1111/jvh.12352.

PMID:
25560841
21.

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H.

J Viral Hepat. 2015 Jan;22 Suppl 1:26-45. doi: 10.1111/jvh.12351.

PMID:
25560840
22.

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.

Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Vree M, Estes C, Flisiak R, Gadano AC, Gane E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanduijav R, Schréter I, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Sokolov S, Souliotis K, Spearman CW, Staub T, Strebkova EA, Struck D, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuure FR, Silva MO, Sypsa V, Gower E.

J Viral Hepat. 2015 Jan;22 Suppl 1:6-25. doi: 10.1111/jvh.12350.

PMID:
25560839
23.

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.

Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11.

PMID:
25467560
24.

Effect of calcium phosphate-based fillers on the structure and bonding strength of novel gelatin-alginate bioadhesives.

Cohen B, Panker M, Zuckerman E, Foox M, Zilberman M.

J Biomater Appl. 2014 May;28(9):1366-75. doi: 10.1177/0885328213509502. Epub 2013 Oct 31.

PMID:
24179064
25.

Vital hepatitis reactivation with anti-tumor necrosis factor-alpha: what do we know?

Zuckerman E.

Isr Med Assoc J. 2013 Jun;15(6):298-300. No abstract available.

26.

Evaluation and treatment of esophageal varices in the cirrhotic patient.

Ashkenazi E, Kovalev Y, Zuckerman E.

Isr Med Assoc J. 2013 Feb;15(2):109-15. Review.

27.

[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].

Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z; Israeli Association for the Study of the Liver.

Harefuah. 2012 Dec;151(12):709-14, 719. Hebrew.

PMID:
23330266
28.

[Treatment of hepatitis C virus--2012: a real breakthrough].

Zuckerman E.

Harefuah. 2012 Dec;151(12):699-704, 719. Review. Hebrew.

PMID:
23330264
29.

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.

Craxi A, Koutsounas S, Ogurtsov P, Chemello L, Maticic M, Torras J, Diago M, Tartaglione MT, Witthoeft T, Yu X, Faruqi R, Chaudhri E, Pedicone LD, Zuckerman E.

J Viral Hepat. 2012 Feb;19(2):e120-5. doi: 10.1111/j.1365-2893.2011.01515.x. Epub 2011 Sep 19.

PMID:
22239509
30.

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.

Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman E, Negro F, Zeuzem S.

Liver Int. 2011 Jul;31 Suppl 2:30-60. doi: 10.1111/j.1478-3231.2011.02539.x. Review.

PMID:
21651702
31.

Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data.

Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, Zeuzem S, Negro F.

Liver Int. 2011 Jul;31 Suppl 2:4-17. doi: 10.1111/j.1478-3231.2011.02535.x.

PMID:
21651700
32.

Familial Mediterranean fever: an association with non-alcoholic fatty liver disease.

Rimar D, Rosner I, Rozenbaum M, Zuckerman E.

Clin Rheumatol. 2011 Jul;30(7):987-91. doi: 10.1007/s10067-011-1718-1. Epub 2011 Mar 2.

PMID:
21360101
33.

Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.

Safadi R, Xie Q, Chen Y, Yin YK, Wei L, Hwang SG, Zuckerman E, Jia JD, Lopez P.

Liver Int. 2011 May;31(5):667-75. doi: 10.1111/j.1478-3231.2010.02360.x. Epub 2010 Oct 29.

PMID:
21040410
34.

Hand-assisted laparoscopic surgery for liver tumors.

Salit Y, Bitterman A, Lefel O, Eisenberg D, Eden A, Barzelai M, Steiner M, Zuckerman E, Haddad R.

Isr Med Assoc J. 2010 Jul;12(7):424-7.

35.

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.

Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr MJ, Günther R, Hultcrantz RW, Spengler U, Lohse AW, Szalay F, Färkkilä M, Pröls M, Strassburg CP; European AIH-BUC-Study Group.

Gastroenterology. 2010 Oct;139(4):1198-206. doi: 10.1053/j.gastro.2010.06.046. Epub 2010 Jun 22.

PMID:
20600032
36.

Distress in older patients with cancer.

Hurria A, Li D, Hansen K, Patil S, Gupta R, Nelson C, Lichtman SM, Tew WP, Hamlin P, Zuckerman E, Gardes J, Limaye S, Lachs M, Kelly E.

J Clin Oncol. 2009 Sep 10;27(26):4346-51. doi: 10.1200/JCO.2008.19.9463. Epub 2009 Aug 3.

37.

Anti-C-reactive protein antibodies in chronic hepatitis C infection: correlation with severity and autoimmunity.

Kessel A, Elias G, Pavlotzky E, Zuckerman E, Rosner I, Toubi E.

Hum Immunol. 2007 Oct;68(10):844-8. Epub 2007 Sep 5.

PMID:
17961773
38.

Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.

Morali G, Maor Y, Klar R, Braun M, Ben Ari Z, Bujanover Y, Zuckerman E, Boger S, Halfon P.

Isr Med Assoc J. 2007 Aug;9(8):588-91.

39.

Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice.

Hurria A, Lichtman SM, Gardes J, Li D, Limaye S, Patil S, Zuckerman E, Tew W, Hamlin P, Abou-Alfa GK, Lachs M, Kelly E.

J Am Geriatr Soc. 2007 Oct;55(10):1604-8. Epub 2007 Aug 14.

PMID:
17697101
40.

Factors of complicated grief pre-death in caregivers of cancer patients.

Tomarken A, Holland J, Schachter S, Vanderwerker L, Zuckerman E, Nelson C, Coups E, Ramirez PM, Prigerson H.

Psychooncology. 2008 Feb;17(2):105-11.

41.

Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity.

Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, Zuckerman E.

J Autoimmun. 2006 Sep;27(2):134-9. Epub 2006 Oct 6.

PMID:
17029886
42.

A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.

Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C.

J Am Geriatr Soc. 2006 Jul;54(7):1119-24.

PMID:
16866685
43.

Aortic involvement in rheumatic diseases.

Slobodin G, Naschitz JE, Zuckerman E, Zisman D, Rozenbaum M, Boulman N, Rosner I.

Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S41-7. Review.

PMID:
16859596
44.

Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.

Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J.

J Am Geriatr Soc. 2006 Jun;54(6):925-31.

PMID:
16776787
45.

Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.

Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C.

Breast Cancer Res Treat. 2006 Aug;98(3):343-8. Epub 2006 Mar 16.

PMID:
16541322
46.

Pregnancy exacerbating hepatopulmonary syndrome.

Sammour RN, Zuckerman E, Tov N, Gonen R.

Obstet Gynecol. 2006 Feb;107(2 Pt 2):455-7.

PMID:
16449147
47.

Developing a cancer-specific geriatric assessment: a feasibility study.

Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L, Kris MG, Noy A, Gomez J, Jakubowski A, Hudis C, Kornblith AB.

Cancer. 2005 Nov 1;104(9):1998-2005.

48.

Nodular regenerative hyperplasia associated with idiopathic thrombocytopenic purpura in a young girl: a case report and review of the literature.

Mahamid J, Miselevich I, Attias D, Laor R, Zuckerman E, Shaoul R.

J Pediatr Gastroenterol Nutr. 2005 Aug;41(2):251-5. Review. No abstract available.

PMID:
16056109
49.

Lamivudine treatment for acute severe hepatitis B: a pilot study.

Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, Safadi R, Lurie Y, Rosner G, Tur-Kaspa R, Reshef R.

Liver Int. 2004 Dec;24(6):547-51. Erratum in: Liver Int. 2005 Feb;25(1):196.

PMID:
15566503
50.

Supplemental Content

Loading ...
Support Center